NCT04894721.

Methods	Trial design: double‐blind RCT with 2 parallel arms Type of record: trial register entry Sample size: 750 Setting: outpatient Country: Argentina Language: English Number of centres: NR Study purpose (treatment, prevention): prevention Trial registration number: NCT04894721 Date of registration: 20 May 2021
Participants	Inclusion criteria Age > 18 years Women of childbearing age with negative pregnancy test In close contact group or epidemiological nexus of a positive COVID‐19 case Able to understand and grant informed consent RT‐PCR with a negative result Exclusion criteria Hypersensitivity or allergy to any component of the drug under evaluation Age < 18 years Use of immunosuppressants (including systemic corticosteroids) in last 30 days Pregnant or lactating Other acute infectious diseases Autoimmune disease or chronic decompensated diseases, or both Received a vaccine for COVID‐19 (1 or 2 doses) or who have received ivermectin (prior to 30 days of the study) or who are participating in another COVID‐19 prophylaxis study
Interventions	Details of intervention Type and dose: ivermectin 0.6 mg/kg, once daily at 1 and 7 days Route of administration: oral Treatment details of control group Placebo Concomitant therapy: standard biosecurity care used in both study arms
Outcomes	Primary study outcome Number of participants diagnosed with COVID‐19 at 14 days Relevant review outcomes planned Number of participants diagnosed with COVID‐19 at 14 days Additional study outcomes Contagion risk within 2 weeks Prophylactic effect associated with patient's pre‐existing comorbidity
Notes	Reason for awaiting classification: study completed, but results not published yet Recruitment status: completed Prospective completion date: October 2021, study completed Planned completion date more than 6 months ago: no Date last update posted: 7 December 2021 Sponsor/funding: Ministry of Public Health, Argentina